Immunome appoints Jean-Jacques Bienaimé as Class II director; initial option grant of $270K

Immunome Inc.

Jean-Jacques Bienaimé appointed as Class II director effective Nov 7, 2023, term through 2025 annual meeting.
Appointed to Audit, Compensation, and Nominating & Corporate Governance Committees.
Receives annual cash retainers totaling $57,500 ($40K board, $7.5K audit, $5K each for comp and nominating).
Granted initial option with Black-Scholes value of $270K vesting quarterly over three years.
Eligible for automatic annual option grants of $135K at each annual meeting, vesting over 12 months.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Jean-Jacques Bienaimé

Class II Director

IMNM · Immunome Inc.

Effective: 2023-11-07
Filed: November 8, 2023, 6:59 PM ET

appointed Jean-Jacques Bienaimé as a Class II director of the Company

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jean-Jacques Bienaimé was appointed as Class II Director at Immunome Inc..

Action: appointed
Role: Class II Director

Exact text from the filing

appointed Jean-Jacques Bienaimé as a Class II director of the Company

View on SEC.gov

Immunome Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-115534

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.